Core Laboratories: 'Spooked The Herd' In June, Things Might Be Looking Up

Fluidsdoc
2023-08-19

ftwitty/E+ via Getty Images

Introduction

Core Laboratories Inc. (NYSE:CLB) turned in a pretty decent quarter that was boosted by some one-off balance sheet adjustments. An $11,600 mm gain from rehoming to the U.S. from the Netherlands was logged, along with the

The Thesis for Core Labs

PGS Revenues (PGS)

Le Peuch-The return of exploration and appraisal across Africa and the Eastern Mediterranean will bring new opportunities for Reservoir Performance in exploration and appraisal. Biguet-Reservoir Performance revenue of $1.6 billion increased 9% sequentially, while margins improved 248 basis points to 18.6%. These increases were primarily due to strong growth internationally, led by the Middle East and Asia. Year-on-year, revenue grew 23% and margins increased 396 basis points driven by strong growth internationally, both on land and offshore.

  • The seismic acquisition market is likely to benefit from the higher exploration and production spending, and a limited supply of seismic vessels.
  • PGS expects full year 2023 gross cash costs to be approximately $550 million. The increase from 2022 is primarily due to the higher activity level and more capacity in operation.
  • 2023 MultiClient cash investments are expected to be approximately $180 million. Approximately 50% of 2023 active 3D vessel time is expected to be allocated to contract work.
  • Capital expenditures for 2023 is expected to be approximately $100 million.
  • The order book amounted to $341 million on June 30, 2023. On March 31, 2023, and June 30, 2022, the Order book was $377 million and $311 million, respectively.

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the U.S. Revenue in the second quarter of 2023 was $83,400,000, up 4% sequentially and up 10% year-over-year.

Citi analyst Scott Gruber lowered his Core Labs' Q2 EBITDA forecast by ~5% to $18.9M, ~6% below consensus, anticipating weakness in North America completions will hurt the Production Enhancement business.

Q2 and Guidance

Guidance

Risks

Your Takeaway

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment